ng28ÄϹ¬Öêʽ»áÉ磨×ܲ¿£º¶«¾©£¬Ê×ϯִÐй٣ºƒÈÌÙÇç·ò£¬ÒÔϼò³Æ¡°ng28ÄϹ¬¡±£©ºÍ¸»Ê¿Ò©Æ·Öêʽ»áÉ磨×ܲ¿£ºˆÎÓñ±h£¬Ê×ϯִÐй٣º¸ßÁø²ýÐÒ£¬ÒÔϼò³Æ¡°¸»Ê¿Ò©Æ·¡±£©Ðû²¼£¬ËûÃÇÒѾÍÓɸ»Ê¿Ò©Æ·Ñз¢ÓÃÓÚÖÎÁƸßÄòËáѪ֢ºÍÍ´·çµÄDotinurad£¨Í¨ÓÃÃû³Æ£©¸æ¿¢Ðí¿ÉÐÒ飬ng28ÄϹ¬½«ÂôÁ¦Æä²úÆ·ÔÚÖйúÊг¡¿ª·¢ºÍÏúÊÛ¡£
ƾ¾ÝÕâ·ÝÐÒ飬ng28ÄϹ¬½«´Ó¸»Ê¿Ò©Æ·»ñµÃDotinuradÔÚÖйúµÄ¶À¼Ò¿ª·¢ºÍÏúÊÛȨ¡£¸»Ê¿Ò©Æ·½«±£´æDotinuradÖƼÁÉú²úÔðÈΣ¬²¢Ïòng28ÄϹ¬ÌṩҩƷ¡£ng28ÄϹ¬½«ÂôÁ¦DotinuradÔÚÖйúµÄÐÂÒ©ÉêÇ룬²¢Ïò¸»Ê¿Ò©Æ·Ö§¸¶Ô¤¸¶¿î¡¢¿ª·¢Àï³Ì±®ºÍÏúÊÛÀï³Ì±®¿îÏî¡£
ÔÚÖйú£¬¸ßÄòËáѪ֢Êǽö´ÎÓÚÌÇÄò²¡µÄµÚ¶þ´ó×î³£¼ûµÄ´úлÐÔ¼²²¡£¬ÖÚËùÖÜÖª£¬ÓëÃÚÄòϵͳ¡¢ÄÚÅÅйϵͳ¡¢´úлϵͳ¡¢ÐÄÄÔѪ¹ÜϵͳµÈÖеĶàÖÖ¼²²¡Óйأ¬°üÀ¨Í´·ç¡£ ±ðµÄ£¬¾ÝÔ¤¼Æ£¬Ä¿Ç°ÔÚÖйú¸ßÄòËáѪ֢»¼ÕßÊýÁ¿Ô¼Îª1.9ÒÚ£¬Í´·ç»¼ÕßÊýÁ¿Ô¼Îª1600Íò1¡£Ëæ×ÅÖйúÉç»á¾¼ÃµÄÉú³¤£¬ÓÉÓÚÉú»î·½·¨ºÍÒûʳϰ¹ßµÄ±ä¸ï£¬Ô¤¼Æ»¼ÕßÈËÊý½«ÔÚ²»¾ÃµÄ½«À´½øÒ»²½Ôö¼Ó¡£
DotinuradÊǸ»Ê¿Ò©Æ·Ñз¢µÄÒ»ÖÖÐÂÐ͵ÄÍ´·çºÍ¸ßÄòËáѪ֢ÖÎÁÆÒ©Îï¡£Dotinuradͨ¹ýÑ¡ÔñÐÔÒÖÖÆÓëÉöÔàÖÐÄòËáÖØÎüÊÕÓйصÄÄòËáÑÎתÔËÂÑ°×£¨URAT1£©£¬ÒÖÖÆÄòËáÖØÎüÊÕ²¢½µµÍѪҺÖÐÄòËáˮƽ¡£
ƾ¾ÝÕâÏîÐÒ飬ng28ÄϹ¬½«¼ÌÐøÔÚÖйú¿ª·¢¸ÃÒ©Æ·£¬²¢ÔÙÉÌÒµ»¯ºó£¬Í¨¹ýng28ÄϹ¬ÔÚÖйúÒµÎñÖлýÀÛµÄ֪ʶºÍÍøÂ磬ΪÉÐδÂú×ãÒ½ÁÆÐèÇóµÄ¸ßÄòËáѪ֢»¼Õß×ö³öТ¾´¡£¸»Ê¿Ò©Æ·ÆÚÍûͨ¹ýÀûÓÃng28ÄϹ¬µÄÒµÎñ»ù´¡½«Ò©Æ·DotinuradÔÚÖйúµÄ¼ÛÖµ×î´ó»¯£¬ÕâÊǸÃÒ©Æ·È«ÇòÍØÕ¹µÄµÚÒ»²½¡£ng28ÄϹ¬ºÍ¸»Ê¿Ò©Æ·Í¨¹ýDotinuradµÄ¿ª·¢ºÍÉÌÒµ»¯£¬½«ÎªÖйúµÄ¸ßÄòËáѪ֢ºÍÍ´·çÌṩеÄÖÎÁÆÑ¡Ôñ£¬²¢ÓÐÖúÓÚ¸ÄÉÆ»¼ÕßµÄÉú»îÖÊÁ¿¡£
ýÌå×Éѯ£º
ng28ÄϹ¬Öêʽ»áÉç
¹«¹²¹Øϵ²¿
+81-(0)3-3817-5120
?
²Î¿¼ 1?For the estimated data regarding the number of patients with hyperuricemia as well as the number of patients with gout: ¡¤??Data of morbidity prevalence rate – Rui Liu et al., Prevalence of Hyperuricemia and Gout in Mainland China from 2000 to 2014: A Systematic Review and Meta-Analysis, BioMed Research International, Volume 2015, Article ID 762820 ¡¤??Estimated data calculated from United Nations World Population Estimates – World Population Prospects, URL£ºhttp://www.un.org/en/development/desa/population/
